Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.44 |
| ▸ | FNTB | P49356 | 9/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875509 | 0.88 | KDM4E (0.40) | FNTAFNTBPPARGKDM4EALDH1A1 | |
| SCHEMBL5510663 | 0.80 | MAPT (0.47) | PPARGKDM4EALDH1A1GAAMAPT | |
| SCHEMBL2875686 | 0.79 | TSPO (0.41) | FNTAFNTBKDM4EALDH1A1GAA | |
| SCHEMBL5521146 | 0.77 | ALDH1A1 (0.47) | FNTAFNTBPPARGKDM4EALDH1A1 | |
| SCHEMBL2872861 | 0.77 | FNTA (0.45) | FNTAFNTBPPARGKDM4EALDH1A1 | |
| SCHEMBL5509134 | 0.77 | GAA (0.46) | FNTAFNTBMEN1KMT2AKDM4E | |
| SCHEMBL5621583 | 0.77 | GAA (0.46) | FNTAFNTBMEN1KMT2AKDM4E | |
| SCHEMBL5511878 | 0.77 | LMNA (0.53) | PPARGKDM4EALDH1A1GAAMAPT | |
| SCHEMBL2875982 | 0.76 | CNR1 (0.45) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL5508823 | 0.76 | ALDH1A1 (0.49) | MEN1KMT2AKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066628-B1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | FNTA 1148/4885FNTB 3042/4885MEN1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.